AstraZeneca's has opened a new R&D centre in the biotech hotspot of Cambridge, Massachusetts, the centrepiece of a $1bn investment in the state.

The UK will accept all 44 proposals made in a recent report on using AI tools in the NHS, including continuous monitoring after deployment.

Shionogi has reached a $2bn agreement to buy Anglo-US biotech IntraBio and its recently approved Aqneursa therapy for two rare genetic disorders.

CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.

Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

Digital health firm Everlywell is rolling out a Clairity AI, which can assess the risk of developing breast cancer from a mammogram, across the US.

As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.

Varda has closed a $251m round to fuel its mission to make medicines in orbit, with TriGemX, Breye, AnaCardio, and ai3Bio also raising new funds.

Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.

Bayer has looked internally for its chief medical officer, appointing Christoph Koenen to the post alongside his current clinical development role.

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.

CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.

Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to distributors in the US.

Former Republican lawmaker Eric Cantor has been named as the new CEO of US pharma group PhRMA, replacing long-serving Stephen Ubl.

uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.

AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.

Sweden's Egetis has won approval in the US for the first-ever treatment for people living with ultra-rare genetic disease MCT8 deficiency.

MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Trump's FDA nominee Heidi Overton was quizzed on a range of issues at her Senate hearing, including vaccines, the abortion pill, and agency reforms.

MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.

The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.

Kyverna has data with miv-cel in stiff person syndrome that shows durable efficacy and safety and seems to sidestep issues flagged with other CAR-Ts.